Alvaro Cobo-Calvo1,2, Sandra Vukusic1,2,3, Romain Marignier1,2,3. 1. Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon. 2. Centre de Reférence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon. 3. Lyon Neurosciences Research Centre, INSERM U1028, CNRS UMR 5292, Lyon 1 University, France.
Abstract
PURPOSE OF REVIEW: The clinical interest for auto-antibodies against myelin oligodendrocyte glycoprotein (MOG) has recently reemerged, with the use of more specific detection methods. Large national cohorts have allowed characterizing a more precise clinical spectrum delineated by the presence of human MOG-antibodies. RECENT FINDINGS: In adults with MOG-antibodies, optic neuritis is the most frequent clinical presentation, with features different from multiple sclerosis (MS), including bilateral involvement and predilection for the anterior part of the optic nerve. Myelitis and brainstem syndrome are also frequent, and may clinically mimic neuromyelitis optica spectrum disorders (NMOSD). Despite the frequently severe clinical presentation, most of patients recover quickly after steroids initiation. Other less typical presentations include encephalitis with seizures, cranial nerve involvement, and chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids-like. Although the majority of adult patients follow a relapsing course, long-term prognosis differs from aquaporin-4-antibodies NMOSD, with only a small proportion of patients with a poor outcome. SUMMARY: MOG-antibodies-associated disease is a new entity in the spectrum of inflammatory demyelinating diseases, distinct from both MS and NMOSD. There is a crucial need to identify factors associated to the risk of relapse or poor outcome, to seek patient subgroups in which immunoactive treatments could be beneficial.
PURPOSE OF REVIEW: The clinical interest for auto-antibodies against myelin oligodendrocyte glycoprotein (MOG) has recently reemerged, with the use of more specific detection methods. Large national cohorts have allowed characterizing a more precise clinical spectrum delineated by the presence of humanMOG-antibodies. RECENT FINDINGS: In adults with MOG-antibodies, optic neuritis is the most frequent clinical presentation, with features different from multiple sclerosis (MS), including bilateral involvement and predilection for the anterior part of the optic nerve. Myelitis and brainstem syndrome are also frequent, and may clinically mimic neuromyelitis optica spectrum disorders (NMOSD). Despite the frequently severe clinical presentation, most of patients recover quickly after steroids initiation. Other less typical presentations include encephalitis with seizures, cranial nerve involvement, and chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids-like. Although the majority of adult patients follow a relapsing course, long-term prognosis differs from aquaporin-4-antibodies NMOSD, with only a small proportion of patients with a poor outcome. SUMMARY:MOG-antibodies-associated disease is a new entity in the spectrum of inflammatory demyelinating diseases, distinct from both MS and NMOSD. There is a crucial need to identify factors associated to the risk of relapse or poor outcome, to seek patient subgroups in which immunoactive treatments could be beneficial.
Authors: Fiona Tea; Joseph A Lopez; Sudarshini Ramanathan; Vera Merheb; Fiona X Z Lee; Alicia Zou; Deepti Pilli; Ellis Patrick; Anneke van der Walt; Mastura Monif; Esther M Tantsis; Eppie M Yiu; Steve Vucic; Andrew P D Henderson; Anthony Fok; Clare L Fraser; Jeanette Lechner-Scott; Stephen W Reddel; Simon Broadley; Michael H Barnett; David A Brown; Jan D Lunemann; Russell C Dale; Fabienne Brilot Journal: Acta Neuropathol Commun Date: 2019-09-03 Impact factor: 7.801
Authors: Sara Mariotto; Sara Carta; Alessandro Dinoto; Giuseppe Lippi; Gian Luca Salvagno; Laura Masin; Daniela Alberti; Romain Marignier; Sergio Ferrari Journal: Eur J Neurol Date: 2022-03-14 Impact factor: 6.089
Authors: Fiona Tea; Deepti Pilli; Sudarshini Ramanathan; Joseph A Lopez; Vera Merheb; Fiona X Z Lee; Alicia Zou; Ganesha Liyanage; Chelsea B Bassett; Selina Thomsen; Stephen W Reddel; Michael H Barnett; David A Brown; Russell C Dale; Fabienne Brilot Journal: Front Immunol Date: 2020-02-06 Impact factor: 7.561